MedTrace Logo

Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)

NCT04962711 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 685

Last updated 2025-05-31

No results posted yet for this study

Summary

This is a prospective study in which a process of identifying and reducing heart failure (HF) risk will be applied to cancer survivors \>55 years old with chemotherapy \>5 years ago.

The overall goal of this study to identify the feasibility and value of risk-guided cardiac rehabilitation (exercise, risk factor modification, and behavioural support) as a component of survivorship care.

Conditions

Interventions

OTHER

Heart Failure intervention (Cardio-Oncology Disease Management Plan (CO-DMP)

A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.

OTHER

Usual care

provided by participants' usual healthcare professional(s)

Sponsors & Collaborators

  • Baker Heart and Diabetes Institute

    lead OTHER

Principal Investigators

  • Thomas H Marwick, MD,PhD,MPH · Baker Heart and Diabetes Institute

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-30
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04962711 on ClinicalTrials.gov